Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
about
Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibThe CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraThe JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia veraA latent form of essential thrombocythemia presenting as portal cavernoma.Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.Peripheral arterial ischemic events in cancer patients.Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.Coagulation and cancer: biological and clinical aspects.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Are MPNs vascular diseases?Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia.Prevalence of venous thromboembolism in patients with secondary polycythemia.Pathophysiology of thrombosis in myeloproliferative neoplasms.An oncolytic parasite to treat polycythemia vera.Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.Raised haematocrit concentration and the risk of death and vascular complications after major surgery.Polycythemia vera: gender-related phenotypic differences.Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.Can ischemia-modified albumin be a valuable indicator of tissue ischemia in polycythemia vera?Outcome of acute limb ischemia in cancer patients.JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status.
P2860
Q30248872-7E3DC917-41BC-41C7-9DBB-23290A220846Q33359341-9E17B930-1082-41F2-95A8-DE4E1AA8583EQ33747797-6FB67E50-49BD-467B-A3C0-8C1E7902D754Q34166617-638737A1-300C-42A4-AA9B-45547682C3DBQ35073857-BA956DA8-CA42-4BA7-A035-CA228DE3592BQ35433005-E9138B45-F82E-4BF3-B7F5-61CA7E1DAD46Q35433259-07829C1C-04CC-4870-B5F5-E474292CE61EQ36563878-ACC8D154-4C39-4C20-AA6E-CE2E2145729AQ36938773-14EF4482-DED4-4CDE-B130-54BB5B46F930Q37406784-38D376BF-B8B3-4029-A8D2-588D60B5A0ABQ37420060-88B7EE19-7049-48F6-8D15-EBF395BF8786Q37565002-6E1DA530-740C-4D40-AAC7-FB619324DBCAQ37812994-07215BA1-5FC7-4124-B004-26AD04259E70Q37860968-B3484678-10E8-42AB-9B69-27DE155819ACQ38070918-1C1801D9-B50B-46D5-A567-3D60F900859CQ38100371-92C4BAD2-D7B6-4E57-93A3-B311662E9BABQ38137750-D4036893-0C0A-409E-9C70-69DC174D632CQ38616947-38196C4D-CFF1-426C-8A56-E041E977AA78Q38706624-958D6599-93D5-4FCD-B5EA-7963D660FEC1Q41113091-B7947990-93BD-479C-91A7-EF96B60D0F66Q42130186-0B2A1475-3FFD-4E6E-AF86-FB3523608EF6Q42586757-9C16A59F-F426-419B-863D-AE945D54B3E9Q42614690-535025A3-14B5-49A3-8A85-CCECB4561FA2Q42790714-0E8C1CE6-7780-4DDD-909A-30D6BEABFFF2Q43451935-A15544F0-64F5-4562-9714-F4A2B0570E2DQ44636061-3E338B15-5738-4094-BDF1-D63998CBC5A5Q45358403-C8488368-2CF1-40FD-83D4-5590138B5E0AQ48257967-A7C96755-75F5-4D63-AC37-24992725E234Q50574609-F2E86226-D0F6-4475-8766-557F6DB592C4Q51752830-944F0D8F-6472-461F-BC9D-A8F02D3EEADDQ54394284-5965B188-D923-463D-A463-55011412F999Q54590271-372B435B-5A62-4E68-8904-07AA0F051302Q54597971-79DC5D1A-5AB7-440C-B680-B419AD36D6C3
P2860
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@en
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@nl
type
label
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@en
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@nl
prefLabel
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@en
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@nl
P2093
P2860
P356
P1433
P1476
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
@en
P2093
L Di Gennaro
R Landolfi
P2860
P2888
P304
P356
10.1038/LEU.2008.253
P577
2008-09-18T00:00:00Z
P5875
P6179
1051383478